萬科企業(02202.HK)獲德宇眾舉牌 與一致行動人持股達5%
格隆匯4月29日丨萬科企業(02202.HK)發佈公吿,公司於2021年4月29日收到深圳市德宇眾實業有限公司及其一致行動人深圳盈安財務顧問企業(有限合夥)、深圳盈嘉眾實業合夥企業(有限合夥)出具的《萬科企業股份有限公司簡式權益變動報吿書》。
2021年4月29日,德宇眾以自有資金通過深圳證券交易所集中競價交易方式買入萬科A股804,800股,佔万科已發行股份的0.01%,導致信息披露義務人及其一致行動人擁有表決權的股份合計達到公司已發行股份的5%。截至2021年4月29日,德宇眾及其一致行動人合計擁有表決權的萬科股份580,886,618股,佔万科總股本的5.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.